[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352748-105":59,"doc-detail-352748-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","new-predicted-dual-cdk-2cdk-1-inhibitors-from-aspergillus-unguis-isolate-sp51-egy-with-relative-selectivity-for-colorectal-cancer-cells-a-computational-and-experimental-approach","New predicted dual CDK-2/CDK-1 inhibitors from Aspergillus unguis isolate SP51-EGY with relative selectivity for colorectal cancer cells - a computational and experimental approach","","Colorectal cancer remains highly lethal, while current chemotherapy struggles with resistance and harming healthy cells. This study evaluates Aspergillus unguis isolate SP51-EGY fungal extract, which shows strong cytotoxicity against HCT116 cells (IC50 3.49 µg/mL) with a selectivity index of 23.33. Computational modeling and phenotypic cellular data propose dual CDK2/1 inhibition, supported by docking and stable molecular dynamics (RMSD \u003C 2.0 Å), predicted ATP-competitive binding, and induction of G1/S and G2/M cell-cycle arrests. Target interactions and drug-like properties motivate biochemical validation.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/new-predicted-dual-cdk-2cdk-1-inhibitors-from-aspergillus-unguis-isolate-sp51-egy-with-relative-selectivity-for-colorectal-cancer-cells-a-computational-and-experimental-approach/352748/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/new-predicted-dual-cdk-2cdk-1-inhibitors-from-aspergillus-unguis-isolate-sp51-egy-with-relative-selectivity-for-colorectal-cancer-cells-a-computational-and-experimental-approach/352748.png","ImageObject",300,407,{"name":92,"@type":93},"Riley West","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What does the fungal extract Aspergillus unguis isolate SP51-EGY show against colorectal cancer cells?","Question",{"text":113,"@type":114},"It exhibits the strongest cytotoxic activity against HCT116 cells, with IC50 = 3.49 µg/mL and a selectivity index of 23.33, indicating relative cytotoxicity toward cancer cells.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How do the computational results support dual CDK2/1 inhibition?",{"text":118,"@type":114},"Molecular docking identifies promising compounds at specific peaks, and stable molecular dynamics (RMSD \u003C 2.0 Å) confirm strong binding. Structural analysis indicates ATP-competitive disruption of CDK/cyclin complexes linked to cell-cycle transitions.",{"name":120,"@type":111,"acceptedAnswer":121},"What cell-cycle outcomes are linked to the predicted CDK2 and CDK1 inhibition?",{"text":122,"@type":114},"The proposed mechanism results in arrest at both G1/S and G2/M checkpoints, consistent with interference in CDK2/cyclin A and CDK1/cyclin A/B complexes.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},352748,1790193245,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1099523885074,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nNew predicted dual CDK-2/CDK- 1 inhibitors from Aspergillus unguis isolate SP51-EGY with relative selectivity for colorectal cancer cells: a computational and experimental approach  \nAhmed A. El-Rashedy1,2, Amal Mosad Ibrahim1, Mohamed S. Abdel-Aziz3, Walid Fayad4 & Faten K. Abd EL-Hady1􀀍  \nColorectal cancer is one of the deadliest cancers in the world. The main problem with cancer treatments is that they need to protect healthy cells. Cyclin-dependent kinases (CDKs), especially CDK-2 and CDK-1, are essential for regulating the cell cycle, cell growth, and tumor genesis. Their dysregulation is frequently detected in colorectal cancer, resulting in uncontrolled cell division and resistance to apoptosis, making them attractive targets for anticancer therapy. The fungal \"Aspergillus unguis isolate SP51-EGY\" “Sh cell”(shake mycelia) extract had the most significant cytotoxic action against HCT116 cancer cells (IC50 = 3.49 µg/mL) and a selectivity index (SI = 23.33), indicating relative cytotoxicity against cancer cells. Computational modeling and cellular phenotypic data suggest a potential mechanism of dual CDK2/1 inhibition, forming a testable hypothesis that requires direct enzymatic validation. Compounds corresponding to peaks [7] and [14] have been tentatively assigned as promising CDK inhibitors based on molecular docking studies; due to their: (1) strong binding affinities (-13 .23 to-46.05 kcal/mol) confirmed by stable molecular dynamics (RMSD \u003C 2.0 Å); (2)  \ncell cycle arrest mediated by dual CDK2/1 inhibition; and (3) favorable drug-like properties, such as molecular weight \u003C 500 Da, good intestinal absorption, and minimal toxicity. Critical interactions with CDK2 (Tyr16, Phe81) and CDK1 (Met88) active site residues were identified by structural analysis. These interactions competed with ATP to disrupt the CDK2 cyclin A andCDK1/cyclin A/B complexes, which resulted in both G1/S and G2/M cell cycle arrests. These integrated computational and cellular findings suggest that the fungal-derived compounds are promising candidates for novel dual CDK2/ CDK1 inhibitors, warranting further experimental validation through biochemical kinase assays.  \nKeywords Aspergillus unguis isolate SP51-EGY, HCT116 cancer, In silico study, CDK-2 and CDK-1 inhibitors  \nCancer remains a leading cause of global mortality, with an estimated 20 million new cases and 9.7 million deaths reported worldwide in 2022, underscoring the persistent demand for effective and safe therapies1. Current chemotherapeutic regimens are frequently hindered by significant challenges, including multidrug resistance, poor solubility, and detrimental side effects on healthy cells2 . This is particularly critical for colorectal cancer (CRC), which is projected to be the third most diagnosed cancer globally, with an anticipated 1.93 million new cases annually by 20253. Despite treatment advances, the 5-year survival rate for CRC patients remains around  \n1Chemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, 33 El Buhouth St., Dokki-Giza 12622, Egypt. 2Department of Organic and Medicinal Chemistry, Faculty of Pharmacy, University of Sadat City, Monofia 32897, Egypt. 3Department of Microbial Chemistry, National Research Centre, Giza 12622, Egypt. 4Drug Bioassay-Cell Culture Laboratory, Pharmacognosy Department, National Research Centre, Giza 12622, Egypt. 􀀍 email: [fk.abdel-hady@nrc.sci.eg](fk.abdel-hady@nrc.sci.eg); [fatenkamal@hotmail.com](fatenkamal@hotmail.com)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \n60%4, and the incidence is expected to rise from 1.15 million in 2020 to 1.92 million by 20405. A central driver of this malignancy—and a key reason for treatment failure—is the dysregulation of core cell cycle machinery, leading to uncontrolled proliferation and resistance to ap","cbCairzsjp90ZEOX","https://ap.wps.com/l/cbCairzsjp90ZEOX","pdf",8123227,26,"English","# Abstract\n## Rationale and therapeutic need\n## Fungal extract cytotoxicity and selectivity\n## Computational docking and molecular dynamics\n## Dual CDK2/1 inhibition mechanism and cell-cycle effects\n## Drug-like properties and key residue interactions\n## Need for enzymatic validation","[{\"question\":\"What does the fungal extract Aspergillus unguis isolate SP51-EGY show against colorectal cancer cells?\",\"answer\":\"It exhibits the strongest cytotoxic activity against HCT116 cells, with IC50 = 3.49 µg/mL and a selectivity index of 23.33, indicating relative cytotoxicity toward cancer cells.\"},{\"question\":\"How do the computational results support dual CDK2/1 inhibition?\",\"answer\":\"Molecular docking identifies promising compounds at specific peaks, and stable molecular dynamics (RMSD \\u003c 2.0 Å) confirm strong binding. Structural analysis indicates ATP-competitive disruption of CDK/cyclin complexes linked to cell-cycle transitions.\"},{\"question\":\"What cell-cycle outcomes are linked to the predicted CDK2 and CDK1 inhibition?\",\"answer\":\"The proposed mechanism results in arrest at both G1/S and G2/M checkpoints, consistent with interference in CDK2/cyclin A and CDK1/cyclin A/B complexes.\"}]","New predicted dual CDK-2/CDK-1 inhibitors from Aspergillus unguis isolate SP51-EGY with relative selectivity for colorectal cancer cells - a computational and experimental approach | PDF",1790101216,66,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/844c6af93fb9eceb3950abf78d827616.webp",983,1291,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b67cdc34d0769af44483f2a2499fd135.webp",982,1290,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/03de785a8c1601f256b5124c958bcaf8.webp",981,1289,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/55b26c839be7e66bb77a2b47e8d71fa1.webp",980,1287]